

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Tuesday March 7, 2017

7:00 a.m. – 8:00 a.m.	Sign-in and Continental Breakfast
8:00 a.m. – 8:15 a.m.	<u>Opening of Steering Committee Meeting</u> Joshua LaBaer, M.D., Ph.D. Arizona State University
8:15 a.m. – 8:20 a.m.	<u>Approval of October, 2016 EDRN Steering Committee Meeting Minutes</u> Joshua LaBaer, M.D., Ph.D., Arizona State University
8:20 a.m. – 9:00 a.m.	<u>State of the EDRN</u> Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute
9:00 a.m. – 9:30 a.m.	<u>TBD</u> William Graves, Ph.D., Arizona State University
9:30 a.m. – 10:00 a.m.	<u>Bioinformatics Resources for the EDRN</u> Guoping Zhao, Ph.D., Shanghai Institutes for Biological Sciences
10:00 a.m. – 10:20 a.m.	Break
10:20 a.m. – 11:00 a.m.	Model EDRN Team Projects <i>Session Moderator:</i> Matt Young, Ph.D., National Cancer Institute
<i>10:20 a.m. – 10:40 a.m.</i>	<u>Colon Cancer Biomarker Bakeoff Project</u> <ul style="list-style-type: none">○ Robert Schoen, M.D., University of Pittsburgh○ Sanford Markowitz, M.D., Ph.D., Case Western Reserve University
<i>10:40 a.m. – 11:00 a.m.</i>	<u>EDRN and DECAMP Lung Cancer Cohorts</u> Pierre Massion, M.D., Vanderbilt-Ingram Cancer Center

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Tuesday March 7, 2017 (Continued)

- 11:00 a.m. – 12:00 p.m.** **Model Projects Supported with CORE Funds**
Session Moderator: Karl Krueger, Ph.D., National Cancer Institute
- 11:00 a.m. – 11:30 a.m.* Prostate Cancer Biomarker Validation Project
Martin Sanda, M.D., Emory University
- 11:30 a.m. – 12:00 p.m.* Capacity/Resource Building Project for
Pancreatic Cancer Supported by CORE Funds
 - Randall Brand, M.D., University of Pittsburgh
 - Brian Haab, Ph.D., Van Andel Research Institute
- 12:00 p.m. – 1:30 p.m.** **Lunch (On Your Own)**
- 1:30 p.m. – 2:00 p.m.** **Discussion on Unblinding, Return of**
Biomarker Data on Reference Sets, and Other
Issues Raised by the DMCC
 - Ziding Feng, Ph.D., The University of Texas MD Anderson Cancer Center
 - Margaret Pepe, Ph.D., Fred Hutchinson Cancer Research Center
- 2:00 p.m. – 3:20 p.m.** **Patenting Biomarkers**
Session Moderator: Sharmistha Ghosh-Janjigian, Ph.D., National Cancer Institute
- 2:00 p.m. – 2:20 p.m.* Title TBD
Lisa A. Haile, J.D., Ph.D., DLA Piper LLP (US)
- 2:20 p.m. – 2:40 p.m.* Title TBD
Chad Borges, Ph.D., Arizona State University

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Tuesday March 7, 2017 (Continued)

Patenting Biomarkers (Continued)

2:40 p.m. – 3:20 p.m.

Panel Discussion

- Josh LaBaer, M.D., Ph.D., Arizona State University
- Lisa A. Haile, J.D., Ph.D., DLA Piper LLP (US)
- Chad Borges, Ph.D., Arizona State University
- Surinder Batra, Ph.D., University of Nebraska
- Daniel Chan, Ph.D., Johns Hopkins University
- Robert Gillies, Ph.D., Moffitt Cancer Center
- Sandy Markowitz, M.D., Ph.D., Case Western Reserve University

3:20 p.m. – 3:40 p.m.

Break

3:40 p.m. – 5:30 p.m.

Developing CLIA and FDA Approved Biomarkers

Session Moderator: Guillermo Márquez, Ph.D., National Cancer Institute

3:40 p.m. – 4:00 p.m.

80 Gene Panel for Lung Cancer

Avrum Spira, M.D., Boston University

4:00 p.m. – 4:20 p.m.

MiPS (Mi Prostate Score Urine test)

Arul Chinnaiyan, M.D., Ph.D., University of Michigan

4:20 p.m. – 4:40 p.m.

Risk of Ovarian Cancer (ROMA)

Steven Skates, Ph.D., Massachusetts General Hospital

4:40 p.m. – 5:00 p.m.

DCEP and AFP-L3 Biomarkers for Liver Cancer

Hiro Yamada, Ph.D., Wako Diagnostics

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Tuesday March 7, 2017 (Continued)

Developing CLIA and FDA Approved Biomarkers (Continued)

5:00 p.m. – 5:30 p.m.

Panel Discussion

- Daniel Chan, Ph.D., Johns Hopkins University
- Avrum Spira, M.D., Boston University
- Arul Chinnaiyan, M.D., Ph.D., University of Michigan
- Steven Skates, Ph.D., Massachusetts General
- Hiro Yamada, Ph.D., Wako Diagnostics

5:30 p.m.

Adjourn for the Day

Wednesday March 8, 2017

7:00 a.m. – 8:00 a.m.

Sign-in and Continental Breakfast

8:00 a.m. – 8:10 a.m.

Charge to Collaborative Groups

Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

8:10 a.m. – 12:00 p.m.

Collaborative Group Meetings

Note: All Collaborative Groups will finalize proposals for use of Set-aside Funds and large validation studies that require Core Funds. Each Collaborative Group will also analyze ongoing validation projects, evaluate their scientific relevance in light current diagnostic needs, and prioritize these projects.

Breast and Gynecological Cancers

- Steven Skates, Ph.D., Massachusetts General Hospital
- Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center
- Christos Patriotis, Ph.D., National Cancer Institute

Gastrointestinal Cancers

- Robert Schoen, M.D., M.P.H., University of Pittsburgh
- Brian Haab, Ph.D., Van Andel Research Institute
- Jo Ann Rinaudo, Ph.D., National Cancer Institute

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Wednesday March 8, 2017 (Continued)

Collaborative Group Meetings (Continued)

Lung and Upper Aerodigestive Cancers

- Pierre Massion, M.D., Vanderbilt -Ingram Cancer Center
- Harvey Pass, M.D., New York University School of Medicine
- Lynn Sorbara, Ph.D., National Cancer Institute

Prostate and Urological Cancers

- Martin Sanda, M.D., Emory University
- John Semmes, Ph.D., Eastern Virginia Medical School
- Jacob Kagan, Ph.D., National Cancer Institute

12:00 p.m. – 1:30 p.m.

EDRN Executive Committee Meeting (Closed Session)

1:30 p.m. – 4:50 p.m.

Reports from Collaborative Groups on Status of Team Projects and Potential Projects to be Session Moderator: NCI Program Director, Ph.D., National Cancer Institute

1:30 p.m.– 2:00 p.m.

Breast Cancer

Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center

2:00 p.m. – 2:30 p.m.

Ovarian Cancer

Steven Skates, Ph.D., Massachusetts General Hospital

2:30 p.m. – 3:00 p.m.

Colon and Esophageal Cancers

Robert Schoen, M.D., University of Pittsburgh

3:00 p.m. – 3:20 p.m.

Break

3:20 p.m. – 3:50 p.m.

Pancreatic Cancer

Brian Haab, Ph.D., Van Andel Research Institute

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Wednesday March 8, 2017 (Continued)

Reports from Collaborative Groups on Status of Team Projects and Potential Projects to be (Continued)

3:50 p.m. – 4:20 p.m.

Lung Cancer

- Pierre Massion M.D., Vanderbilt -Ingram Cancer Center
- Harvey Pass, M.D., New York University School of Medicine

4:20 p.m. – 4:50 p.m.

Prostate Cancer

- Martin Sanda, M.D., Emory University
- John Semmes, Ph.D., Eastern Virginia Medical School

4:50 p.m.

Adjourn for the Day

Thursday March 9, 2017

7:00 a.m. – 8:00 a.m.

Sign-in and Continental Breakfast

8:00 a.m. – 9:20 a.m.

Proteomic Platforms: Unique platforms that might be of use to others
Session Moderator: TBD

8:00 a.m. – 8:20 a.m.

TBD

John Semmes, Ph.D., Eastern Virginia Medical School

8:20 a.m. – 8:40 a.m.

TBD

Amanda Paulovich, M.D., Ph.D., Fred Hutchison Research Cancer Center

8:40 a.m. – 9:00 a.m.

TBD

Paul Lampe, Ph.D., Fred Hutchinson Cancer Research Center

9:00 a.m. – 9:20 a.m.

TBD

Zhen Zhang, Ph.D., Johns Hopkins University

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Thursday March 9, 2017 (Continued)

- | | |
|--------------------------------|---|
| 9:20 a.m. – 9:40 a.m. | Break |
| 9:40 a.m. – 11:00 a.m. | Genomics Platforms: Platforms that might be of use to others
<i>Session Moderator:</i> Richard Mazurchuk, Ph.D., National Cancer Institute |
| <i>9:40 a.m. – 10:00 a.m.</i> | <u>TBD</u>
Paul Boutros, Ph.D., Ontario Institute of Cancer Research |
| <i>10:00 a.m. – 10:20 a.m.</i> | <u>TBD</u>
James Herman, M.D., University of Pittsburgh |
| <i>10:20 a.m. – 10:40 a.m.</i> | <u>TBD</u>
Louise Showe, Ph.D., Wister Institute |
| <i>10:40 a.m. – 11:00 a.m.</i> | <u>TBD</u>
Scott Tomlins, Ph.D., University of Michigan |
| 11:00 a.m. – 11:10 a.m. | Final Remarks <ul style="list-style-type: none">○ Joshua LaBaer, M.D., Ph.D., Arizona State University○ Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute |
| 11:10 a.m. | Adjourn |